About this Journal Submit a Manuscript Table of Contents
Journal of Amino Acids
Volume 2011 (2011), Article ID 207691, 13 pages
http://dx.doi.org/10.4061/2011/207691
Review Article

Small Changes Huge Impact: The Role of Protein Posttranslational Modifications in Cellular Homeostasis and Disease

1Department of Biochemistry, Cellular & Molecular Biology, Lombardi Comprehensive Cancer Center, Georgetown University School of Medicine, 3900 Reservoir Road, NW, Washington DC 20057, USA
2Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University School of Medicine, Washington, DC 20057, USA

Received 23 February 2011; Accepted 18 April 2011

Academic Editor: Zulfiqar Ahmad

Copyright © 2011 Tejaswita M. Karve and Amrita K. Cheema. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. X. Li and T. M. Kapoor, “Approach to profile proteins that recognize post-translationally modified histone "tails",” Journal of the American Chemical Society, vol. 132, no. 8, pp. 2504–2505, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  2. N. Sundararajan, D. Mao, S. Chan et al., “Ultrasensitive detection and characterization of posttranslational modifications using surface-enhanced Raman spectroscopy,” Analytical Chemistry, vol. 78, no. 11, pp. 3543–3550, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  3. N. Khidekel and L. C. Hsieh-Wilson, “A 'molecular switchboard'—covalent modifications to proteins and their impact on transcription,” Organic and Biomolecular Chemistry, vol. 2, no. 1, pp. 1–7, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  4. W. H. McDonald and J. R. Yates, “Shotgun proteomics and biomarker discovery,” Disease Markers, vol. 18, no. 2, pp. 99–105, 2002. View at Scopus
  5. C. Wang, et al., “Acetylation and nuclear receptor action,” The Journal of Steroid Biochemistry and Molecular Biology, vol. 123, no. 3–5, pp. 91–100, 2011. View at Scopus
  6. J. K. Choi and L. J. Howe, “Histone acetylation: truth of consequences?” Biochemistry and Cell Biology, vol. 87, no. 1, pp. 139–150, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  7. M. Arif, P. Senapati, J. Shandilya, and T. K. Kundu, “Protein lysine acetylation in cellular function and its role in cancer manifestation,” Biochimica et Biophysica Acta, vol. 1799, no. 10–12, pp. 702–716, 2010. View at Publisher · View at Google Scholar · View at PubMed
  8. M. A. Glozak, N. Sengupta, X. Zhang, and E. Seto, “Acetylation and deacetylation of non-histone proteins,” Gene, vol. 363, no. 1-2, pp. 15–23, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  9. R. Chammas, J. L. Sonnenburg, N. E. Watson et al., “De-N-acetyl-gangliosides in humans: unusual subcellular distribution of a novel tumor antigen,” Cancer Research, vol. 59, no. 6, pp. 1337–1346, 1999. View at Scopus
  10. M. P. Mattson, “Acetylation unleashes protein demons of dementia,” Neuron, vol. 67, no. 6, pp. 900–902, 2010. View at Publisher · View at Google Scholar · View at PubMed
  11. S. Peleg, F. Sananbenesi, A. Zovoilis et al., “Altered histone acetylation is associated with age-dependent memory impairment in mice,” Science, vol. 328, no. 5979, pp. 753–756, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  12. Z. Lu, I. Scott, B. R. Webster, and M. N. Sack, “The emerging characterization of lysine residue deacetylation on the modulation of mitochondrial function and cardiovascular biology,” Circulation Research, vol. 105, no. 9, pp. 830–841, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  13. A. K. Voss and T. Thomas, “MYST family histone acetyltransferases take center stage in stem cells and development,” BioEssays, vol. 31, no. 10, pp. 1050–1061, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  14. W. K. Maas, G. D. Novelli, and F. Lipmann, “Acetylation of glutamic acid by extracts of Escherichia coli,” Proceedings of the National Academy of Sciences of the United States of America, vol. 39, no. 10, pp. 1004–1008, 1953.
  15. Y.-T. Wu, S.-B. Wu, W.-Y. Lee, and Y.-H. Wei, “Mitochondrial respiratory dysfunction-elicited oxidative stress and posttranslational protein modification in mitochondrial diseases,” Annals of the New York Academy of Sciences, vol. 1201, pp. 147–156, 2010. View at Publisher · View at Google Scholar · View at PubMed
  16. K. K. Bhakat, S. K. Mokkapati, I. Boldogh, T. K. Hazra, and S. Mitra, “Acetylation of human 8-oxoguanine-DNA glycosylase by p300 and its role in 8-oxoguanine repair in vivo,” Molecular and Cellular Biology, vol. 26, no. 5, pp. 1654–1665, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  17. G. Arunachalam, H. Yao, I. K. Sundar, S. Caito, and I. Rahman, “SIRT1 regulates oxidant- and cigarette smoke-induced eNOS acetylation in endothelial cells: role of resveratrol,” Biochemical and Biophysical Research Communications, vol. 393, no. 1, pp. 66–72, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  18. O. M. Sobulo, J. Borrow, R. Tomek et al., “MLL is fused to CBP, a histone acetyltransferase, in therapy-related acute myeloid leukemia with a t(11;16)(q23;p13.3),” Proceedings of the National Academy of Sciences of the United States of America, vol. 94, no. 16, pp. 8732–8737, 1997. View at Publisher · View at Google Scholar · View at Scopus
  19. J. Patel, R. R. Pathak, and S. Mujtaba, “The biology of lysine acetylation integrates transcriptional programming and metabolism,” Nutrition and Metabolism, vol. 8, p. 12, 2011. View at Publisher · View at Google Scholar · View at PubMed
  20. I. Dalle-Donne, G. Aldini, M. Carini, R. Colombo, R. Rossi, and A. Milzani, “Protein carbonylation, cellular dysfunction, and disease progression,” Journal of Cellular and Molecular Medicine, vol. 10, no. 2, pp. 389–406, 2006. View at Publisher · View at Google Scholar · View at Scopus
  21. C. M. Wong, L. Marcocci, L. Liu, and Y. J. Suzuki, “Cell signaling by protein carbonylation and decarbonylation,” Antioxidants and Redox Signaling, vol. 12, no. 3, pp. 393–404, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  22. G. Wang, J. Wang, H. Ma, and M. F. Khan, “Increased nitration and carbonylation of proteins in MRL +/+ mice exposed to trichloroethene: potential role of protein oxidation in autoimmunity,” Toxicology and Applied Pharmacology, vol. 237, no. 2, pp. 188–195, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  23. K. R. Atkuri, T. M. Cowan, T. Kwan et al., “Inherited disorders affecting mitochondrial function are associated with glutathione deficiency and hypocitrullinemia,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 10, pp. 3941–3945, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  24. T. Nyström, “Role of oxidative carbonylation in protein quality control and senescence,” EMBO Journal, vol. 24, no. 7, pp. 1311–1317, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  25. A. G. Madian and F. E. Regnier, “Proteomic identification of carbonylated proteins and their oxidation sites,” Journal of Proteome Research, vol. 9, no. 8, pp. 3766–3780, 2010. View at Publisher · View at Google Scholar · View at PubMed
  26. B. W. Newton, W. K. Russell, D. H. Russell, S. K. Ramaiah, and A. Jayaraman, “Liver proteome analysis in a rodent model of alcoholic steatosis,” Journal of Proteome Research, vol. 8, no. 4, pp. 1663–1671, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  27. E. Barreiro, D. Sánches, J. B. Gáldiz, S. N. A. Hussain, and J. Gea, “N-acetylcysteine increases manganese superoxide dismutase activity in septic rat diaphragms,” European Respiratory Journal, vol. 26, no. 6, pp. 1032–1039, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  28. T. Kabuta, R. Setsuie, T. Mitsui et al., “Aberrant molecular properties shared by familial Parkinson's disease-associated mutant UCH-L1 and carbonyl-modified UCH-L1,” Human Molecular Genetics, vol. 17, no. 10, pp. 1482–1496, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  29. J. Choi, M. C. Sullards, J. A. Olzmann et al., “Oxidative damage of DJ-1 is linked to sporadic Parkinson and Alzheimer diseases,” Journal of Biological Chemistry, vol. 281, no. 16, pp. 10816–10824, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  30. A. G. Madian and F. E. Regnier, “Proteomic identification of carbonylated proteins and their oxidation sites,” Journal of Proteome Research, vol. 9, no. 8, pp. 3766–3780, 2010. View at Publisher · View at Google Scholar · View at PubMed
  31. A. Varki and N. Sharon, “Historical background and overview,” in Essentials of Glycobiology, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, USA, 2009.
  32. A. Varki and J. B. Lowe, Biological Roles of Glycans, 2009.
  33. J. F. Rakus and L. K. Mahal, “New technologies for glycomic analysis: toward a systematic understanding of the glycome,” Annual Review of Analytical Chemistry, vol. 4, no. 1, pp. 367–392, 2011.
  34. J. Xue, Q. Zhao, L. Zhu, and W. Zhang, “Deglycosylation of FcαR at N58 increases its binding to IgA,” Glycobiology, vol. 20, no. 7, pp. 905–915, 2010. View at Publisher · View at Google Scholar · View at PubMed
  35. J. D. Méndez, J. Xie, M. Aguilar-Hernández, and V. Méndez-Valenzuela, “Trends in advanced glycation end products research in diabetes mellitus and its complications,” Molecular and Cellular Biochemistry, vol. 341, no. 1-2, pp. 33–41, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  36. T. G. Szabá, R. Palotai, P. Antal et al., “Critical role of glycosylation in determining the length and structure of T cell epitopes,” Immunome Research, vol. 5, no. 1, Article ID 4, 2009. View at Publisher · View at Google Scholar · View at PubMed
  37. M. Broncel, J. A. Falenski, S. C. Wagner, C. P. R. Hackenberger, and B. Koksch, “How post-translational modifications influence amyloid formation: a systematic study of phosphorylation and glycosylation in model peptides,” Chemistry, vol. 16, no. 26, pp. 7881–7888, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  38. M. K. Salamat, M. Dron, J. Chapuis, C. Langevin, and H. Laude, “Prion propagation in cells expressing PrP glycosylation mutants,” Journal of Virology, vol. 85, no. 7, pp. 3077–3085, 2011. View at Publisher · View at Google Scholar · View at PubMed
  39. Y. Lee, M. Kockx, M. J. Raftery, W. Jessup, R. Griffith, and L. Kritharides, “Glycosylation and sialylation of macrophage-derived human apolipoprotein E analyzed by SDS-PAGE and mass spectrometry: evidence for a novel site of glycosylation on SER290,” Molecular and Cellular Proteomics, vol. 9, no. 9, pp. 1968–1981, 2010. View at Publisher · View at Google Scholar · View at PubMed
  40. H. J. F. MacCioni, R. Quiroga, and M. L. Ferrari, “Cellular and molecular biology of glycosphingolipid glycosylation,” Journal of Neurochemistry, vol. 117, no. 4, pp. 589–602, 2011. View at Publisher · View at Google Scholar · View at PubMed
  41. J. D. Méndez, J. Xie, M. Aguilar-Hernández, and V. Méndez-Valenzuela, “Molecular susceptibility to glycation and its implication in diabetes mellitus and related diseases,” Molecular and Cellular Biochemistry, vol. 344, no. 1-2, pp. 185–193, 2010. View at Publisher · View at Google Scholar · View at PubMed
  42. R. H. Nagaraj, M. Linetsky, and A. W. Stitt, “The pathogenic role of Maillard reaction in the aging eye,” Amino Acids, 2010. In press. View at Publisher · View at Google Scholar · View at PubMed
  43. N. Ahmed, “Advanced glycation endproducts—role in pathology of diabetic complications,” Diabetes Research and Clinical Practice, vol. 67, no. 1, pp. 3–21, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  44. B. C. Creagh-Brown, G. J. Quinlan, T. W. Evans, and A. Burke-Gaffney, “The RAGE axis in systemic inflammation, acute lung injury and myocardial dysfunction: an important therapeutic target?” Intensive Care Medicine, vol. 36, no. 10, pp. 1644–1656, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  45. D. S. Alonzi and T. D. Butters, “Therapeutic targets for inhibitors of glycosylation,” Chimia, vol. 65, no. 1-2, pp. 35–39, 2011. View at Publisher · View at Google Scholar
  46. R. A. Dwek, T. D. Butters, F. M. Platt, and N. Zitzmann, “Targeting glycosylation as a therapeutic approach,” Nature Reviews Drug Discovery, vol. 1, no. 1, pp. 65–75, 2002. View at Scopus
  47. P. K. Sengupta, M. P. Bouchie, and M. A. Kukuruzinska, “N-glycosylation gene DPAGT1 is a target of the Wnt/β-catenin signaling pathway,” Journal of Biological Chemistry, vol. 285, no. 41, pp. 31164–31173, 2010. View at Publisher · View at Google Scholar · View at PubMed
  48. D. J. Prockop and K. Juva, “Synthesis of hydroxyproline in vitro by the hydroxylation of proline in a precursor of collagen,” Proceedings of the National Academy of Sciences of the United States of America, vol. 53, pp. 661–668, 1965.
  49. C. I. Levene, C. D. Ockleford, and C. L. Barber, “Scurvy: a comparison between ultrastructural and biochemical changes observed in cultured fibroblasts and the collagen they synthesise,” Virchows Archiv Abteilung B Cell Pathology, vol. 23, no. 4, pp. 325–338, 1977. View at Scopus
  50. K. I. Kivirikko, R. Myllylä, and T. Pihlajaniemi, “Protein hydroxylation: prolyl 4-hydroxylase, an enzyme with four cosubstrates and a multifunctional subunit,” The FASEB Journal, vol. 3, no. 5, pp. 1609–1617, 1989. View at Scopus
  51. D. D. Van Slyke and F. M. Sinex, “The course of hydroxylation of lysine to form hydroxylysine in collagen,” The Journal of Biological Chemistry, vol. 232, no. 2, pp. 797–806, 1958. View at Scopus
  52. P. Jaakkola, D. R. Mole, Y. M. Tian et al., “Targeting of HIF-α to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation,” Science, vol. 292, no. 5516, pp. 468–472, 2001. View at Scopus
  53. D. Lando, D. J. Peet, D. A. Whelan, J. J. Gorman, and M. L. Whitelaw, “Asparagine hydroxylation of the HIF transactivation domain: a hypoxic switch,” Science, vol. 295, no. 5556, pp. 858–861, 2002. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  54. A. Siddiq, L. R. Aminova, and R. R. Ratan, “Hypoxia inducible factor prolyl 4-hydroxylase enzymes: center stage in the battle against hypoxia, metabolic compromise and oxidative stress,” Neurochemical Research, vol. 32, no. 4-5, pp. 931–946, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  55. D. A. Chan, P. D. Sutphin, N. C. Denko, and A. J. Giaccia, “Role of prolyl hydroxylation in oncogenically stabilized hypoxia-inducible factor-1α,” Journal of Biological Chemistry, vol. 277, no. 42, pp. 40112–40117, 2002. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  56. J. Myllyharju, “HIF prolyl 4-hydroxylases and their potential as drug targets,” Current Pharmaceutical Design, vol. 15, no. 33, pp. 3878–3885, 2009. View at Publisher · View at Google Scholar · View at Scopus
  57. L.-L. Hu, S. Niu, T. Huang, K. Wang, X.-H. Shi, and Y.-D. Cai, “Prediction and analysis of protein hydroxyproline and hydroxylysine,” PLoS One, vol. 5, no. 12, p. e15917, 2010. View at Publisher · View at Google Scholar · View at PubMed
  58. P. F. Fitzpatrick, “Mechanism of aromatic amino acid hydroxylation,” Biochemistry, vol. 42, no. 48, pp. 14083–14091, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  59. N. Blau, F. J. van Spronsen, and H. L. Levy, “Phenylketonuria,” Lancet, vol. 376, no. 9750, pp. 1417–1427, 2010.
  60. H. Hedstrand, O. Ekwall, J. Haavik et al., “Identification of tyrosine hydroxylase as an autoantigen in autoimmune polyendocrine syndrome type I,” Biochemical and Biophysical Research Communications, vol. 267, no. 1, pp. 456–461, 2000. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  61. M. Ohno, M. Okamoto, N. Kawabe et al., “Oudenone, a novel tyrosine hydroxylase inhibitor from microbial origin,” Journal of the American Chemical Society, vol. 93, no. 5, pp. 1285–1286, 1971. View at Scopus
  62. S. Ayukawa, T. Takeuchi, M. Sezaki, T. Hara, and H. Umezawa, “Inhibition of tyrosine hydroxylase by aquayamycin,” Journal of Antibiotics, vol. 21, no. 5, pp. 350–353, 1968. View at Scopus
  63. L. Wang, H. Erlandsen, J. Haavik, P. M. Knappskog, and R. C. Stevens, “Three-dimensional structure of human tryptophan hydroxylase and its implications for the biosynthesis of the neurotransmitters serotonin and melatonin,” Biochemistry, vol. 41, no. 42, pp. 12569–12574, 2002. View at Publisher · View at Google Scholar · View at Scopus
  64. M. R. W. Mann and M. S. Bartolomei, “Epigenetic reprogramming in the mammalian embryo: struggle of the clones,” Genome Biology, vol. 3, no. 2, pp. 1–4, 2002. View at Scopus
  65. I. C. G. Weaver, “Epigenetic programming by maternal behavior and pharmacological intervention—nature versus nurture: let's call the whole thing off,” Epigenetics, vol. 2, no. 1, pp. 22–28, 2007. View at Scopus
  66. N. P. B. Dudman, X.-W. Guo, R. B. Gordon, P. A. Dawson, and D. E. L. Wilcken, “Human homocysteine catabolism: three major pathways and their relevance to development of arterial occlusive disease,” Journal of Nutrition, vol. 126, no. 4, supplement, pp. 1295S–1300S, 1996.
  67. J. M. Wagner, B. Hackanson, M. Lübbert, and M. Jung, “Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy,” Clinical Epigenetics, vol. 1, no. 3-4, pp. 117–136, 2010. View at Publisher · View at Google Scholar · View at PubMed
  68. M. L. Katz and M. Rodrigues, “Juvenile ceroid lipofuscinosis. Evidence for methylated lysine in neural storage body protein,” American Journal of Pathology, vol. 138, no. 2, pp. 323–332, 1991. View at Scopus
  69. X. D. Yang, A. Lamb, and L. F. Chen, “Methylation, a new epigenetic mark for protein stability,” Epigenetics, vol. 4, no. 7, pp. 429–433, 2009. View at Publisher · View at Google Scholar · View at Scopus
  70. E. M. Duncan and C. D. Allis, “Errors in erasure: links between histone lysine methylation removal and disease,” Progress in Drug Research, vol. 67, pp. 69–90, 2011.
  71. M. D. Litt, M. Simpson, M. Gaszner, C. D. Allis, and G. Felsenfeld, “Correlation between histone lysine methylation and developmental changes at the chicken β-globin locus,” Science, vol. 293, no. 5539, pp. 2453–2455, 2001. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  72. J. T. Brosnan, R. L. Jacobs, L. M. Stead, and M. E. Brosnan, “Methylation demand: a key determinant of homocysteine metabolism,” Acta Biochimica Polonica, vol. 51, no. 2, pp. 405–413, 2004. View at Scopus
  73. H. Ischiropoulos, “Protein tyrosine nitration—an update,” Archives of Biochemistry and Biophysics, vol. 484, no. 2, pp. 117–121, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  74. N. Abello, H. A. M. Kerstjens, D. S. Postma, and R. Bischoff, “Protein tyrosine nitration: selectivity, physicochemical and biological consequences, denitration, and proteomics methods for the identification of tyrosine-nitrated proteins,” Journal of Proteome Research, vol. 8, no. 7, pp. 3222–3238, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  75. V. A. Yakovlev and R. B. Mikkelsen, “Protein tyrosine nitration in cellular signal transduction pathways,” Journal of Receptors and Signal Transduction, vol. 30, no. 6, pp. 420–429, 2010. View at Publisher · View at Google Scholar · View at PubMed
  76. Y. B. Blume, Y. A. Krasylenko, and A. I. Yemets, “Tyrosine nitration as regulatory posttranslational modification of proteins,” Ukrainskii Biokhimicheskii Zhurnal, vol. 81, no. 5, pp. 5–15, 2009. View at Scopus
  77. G. O. Osoata, S. Yamamura, M. Ito et al., “Nitration of distinct tyrosine residues causes inactivation of histone deacetylase 2,” Biochemical and Biophysical Research Communications, vol. 384, no. 3, pp. 366–371, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  78. N. Wang, D. Li, N. H. Lu, L. Yi, X. W. Huang, and Z. H. Gao, “Peroxynitrite and hemoglobin-mediated nitrative/oxidative modification of human plasma protein: effects of some flavonoids,” Journal of Asian Natural Products Research, vol. 12, no. 4, pp. 257–264, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  79. M. A. Abdelsaid, B. A. Pillai, S. Matragoon, R. Prakash, M. Al-Shabrawey, and A. B. El-Remessy, “Early intervention of tyrosine nitration prevents vaso-obliteration and neovascularization in ischemic retinopathy,” Journal of Pharmacology and Experimental Therapeutics, vol. 332, no. 1, pp. 125–134, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  80. S. R. Danielson, J. M. Held, B. Schilling, M. Oo, B. W. Gibson, and J. K. Andersen, “Preferentially increased nitration of α-synuclein at tyrosine-39 in a cellular oxidative model of Parkinson's disease,” Analytical Chemistry, vol. 81, no. 18, pp. 7823–7828, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  81. K. K. K. Chung, “Modulation of pro-survival proteins by S-nitrosylation: implications for neurodegeneration,” Apoptosis, vol. 15, no. 11, pp. 1364–1370, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  82. L. S. Murdaugh, Z. Wang, L. V. Del Priore, J. Dillon, and E. R. Gaillard, “Age-related accumulation of 3-nitrotyrosine and nitro-A2E in human Bruch's membrane,” Experimental Eye Research, vol. 90, no. 5, pp. 564–571, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  83. J. M. Souza, G. Peluffo, and R. Radi, “Protein tyrosine nitration—functional alteration or just a biomarker?” Free Radical Biology and Medicine, vol. 45, no. 4, pp. 357–366, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  84. T. Mdol, C. Natal, M. P. Pérez De Obanos, E. Domingo De Miguel, M. J. Iraburu, and M. J. López-Zabalza, “Apoptosis of hepatic stellate cells mediated by specific protein nitration,” Biochemical Pharmacology, vol. 81, no. 3, pp. 451–458, 2011. View at Publisher · View at Google Scholar · View at PubMed
  85. F. X. Guix, G. Ill-Raga, R. Bravo et al., “Amyloid-dependent triosephosphate isomerase nitrotyrosination induces glycation and tau fibrillation,” Brain, vol. 132, no. 5, pp. 1335–1345, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  86. I. I. Singer, D. W. Kawka, S. Scott et al., “Expression of inducible nitric oxide synthase and nitrotyrosine in colonic epithelium in inflammatory bowel disease,” Gastroenterology, vol. 111, no. 4, pp. 871–885, 1996. View at Scopus
  87. D. I. Mundy, “Protein palmitoylation in membrane trafficking,” Biochemical Society Transactions, vol. 23, no. 3, pp. 572–576, 1995. View at Scopus
  88. C. Salaun, J. Greaves, and L. H. Chamberlain, “The intracellular dynamic of protein palmitoylation,” Journal of Cell Biology, vol. 191, no. 7, pp. 1229–1238, 2010. View at Publisher · View at Google Scholar · View at PubMed
  89. K. M. Druey, O. Ugur, J. M. Caron, C. K. Chen, P. S. Backlund, and T. L. Z. Jones, “Amino-terminal cysteine residues of RGS16 are required for palmitoylation and modulation of G(i)- and G(q)-mediated signaling,” Journal of Biological Chemistry, vol. 274, no. 26, pp. 18836–18842, 1999. View at Publisher · View at Google Scholar · View at Scopus
  90. D. Du, B. M. Raaka, H. Grimberg, M. Lupu-Meiri, Y. Oron, and M. C. Gershengorn, “Carboxyl tail cysteine mutants of the thyrotropin-releasing hormone receptor type 1 exhibit constitutive signaling: role of palmitoylation,” Molecular Pharmacology, vol. 68, no. 1, pp. 204–209, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  91. N. A. Pfender, S. Grosch, G. Roussel, M. Koch, E. Trifilieff, and J. M. Greer, “Route of uptake of palmitoylated encephalitogenic peptides of myelin proteolipid protein by antigen-presenting cells: importance of the type of bond between lipid chain and peptide and relevance to autoimmunity,” Journal of Immunology, vol. 180, no. 3, pp. 1398–1404, 2008. View at Scopus
  92. X. Meckler, J. Roseman, P. Das et al., “Reduced Alzheimer's disease β-amyloid deposition in transgenic mice expressing S-palmitoylation-deficient APH1aL and nicastrin,” Journal of Neuroscience, vol. 30, no. 48, pp. 16160–16169, 2010. View at Publisher · View at Google Scholar · View at PubMed
  93. X. Wei, J. G. Schneider, S. M. Shenouda et al., “De Novo lipogenesis maintains vascular homeostasis through endothelial nitric-oxide synthase (eNOS) palmitoylation,” Journal of Biological Chemistry, vol. 286, no. 4, pp. 2933–2945, 2011. View at Publisher · View at Google Scholar · View at PubMed
  94. A. Yanai, K. Huang, R. Kang et al., “Palmitoylation of huntingtin by HIP14is essential for its trafficking and function,” Nature Neuroscience, vol. 9, no. 6, pp. 824–831, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  95. N. Majeau, R. Frometin, C. Savard, M. Duval, M. J. Tremblay, and D. Leclerc, “Palmitoylation of hepatitis C virus core protein is important for virion production,” Journal of Biological Chemistry, vol. 284, no. 49, pp. 33915–33925, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  96. B. Cuiffo and R. Ren, “Palmitoylation of oncogenic NRAS is essential for leukemogenesis,” Blood, vol. 115, no. 17, pp. 3598–3605, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  97. L. Li, L. Dong, L. Xia, T. Li, and H. Zhong, “Chemical and genetic probes for analysis of protein palmitoylation,” Journal of Chromatography B, vol. 879, no. 17-18, pp. 1316–1324, 2011. View at Publisher · View at Google Scholar · View at PubMed
  98. T. Hunter, “Protein kinases and phosphatases: the yin and yang of protein phosphorylation and signaling,” Cell, vol. 80, no. 2, pp. 225–236, 1995. View at Scopus
  99. G. Ghosh and J. A. Adams, “Phosphorylation mechanism and structure of serine-arginine protein kinases,” FEBS Journal, vol. 278, no. 4, pp. 587–597, 2011. View at Publisher · View at Google Scholar · View at PubMed
  100. Y.-Y. Yeh, K. Wrasman, and P. K. Herman, “Autophosphorylation within the Atg1 activation loop is required for both kinase activity and the induction of autophagy in Saccharomyces cerevisiae,” Genetics, vol. 185, no. 3, pp. 871–882, 2010. View at Publisher · View at Google Scholar · View at PubMed
  101. A. J. Levine and A. M. Puzio-Kuter, “The control of the metabolic switch in cancers by oncogenes and tumor suppressor genes,” Science, vol. 330, no. 6009, pp. 1340–1344, 2010. View at Publisher · View at Google Scholar · View at PubMed
  102. T. A. J. Haystead, A. T. R. Sim, D. Carling et al., “Effects of the tumour promoter okadaic acid on intracellular protein phosphorylation and metabolism,” Nature, vol. 337, no. 6202, pp. 78–81, 1989. View at Scopus
  103. T. Patschinsky, T. Hunter, and F. S. Esch, “Analysis of the sequence of amino acids surrounding sites of tyrosine phosphorylation,” Proceedings of the National Academy of Sciences of the United States of America, vol. 79, no. 4, pp. 973–977, 1982. View at Scopus
  104. J. P. Anderson, D. E. Walker, J. M. Goldstein et al., “Phosphorylation of Ser-129 is the dominant pathological modification of α-synuclein in familial and sporadic lewy body disease,” Journal of Biological Chemistry, vol. 281, no. 40, pp. 29739–29752, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  105. J. Zhao, M. Xin, T. Wang, Y. Zhang, and X. Deng, “Nicotine enhances the antiapoptotic function of mcl-1 through phosphorylation,” Molecular Cancer Research, vol. 7, no. 12, pp. 1954–1961, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  106. L. F. Hernandez-Aya and A. M. Gonzalez-Angulo, “Targeting the phosphatidylinositol 3-kinase signaling pathway in breast cancer,” Oncologist, vol. 16, no. 4, pp. 404–414, 2011. View at Publisher · View at Google Scholar · View at PubMed
  107. N. J. MacLaine and T. R. Hupp, “How phosphorylation controls p53,” Cell Cycle, vol. 10, no. 6, pp. 916–921, 2011. View at Publisher · View at Google Scholar
  108. S. G. Julien, N. Dubé, S. Hardy, and M. L. Tremblay, “Inside the human cancer tyrosine phosphatome,” Nature Reviews Cancer, vol. 11, no. 1, pp. 35–49, 2011. View at Publisher · View at Google Scholar · View at PubMed
  109. H. C. Harsha and A. Pandey, “Phosphoproteomics in cancer,” Molecular Oncology, vol. 4, no. 6, pp. 482–495, 2010. View at Publisher · View at Google Scholar · View at PubMed
  110. G. K. Kolluru, J. H. Siamwala, and S. Chatterjee, “eNOS phosphorylation in health and disease,” Biochimie, vol. 92, no. 9, pp. 1186–1198, 2010. View at Publisher · View at Google Scholar · View at PubMed
  111. F. Yoboua, A. Martel, A. Duval, E. Mukawera, and N. Grandvaux, “Respiratory syncytial virus-mediated NF-κB p65 phosphorylation at serine 536 is dependent on RIG-I, TRAF6, and IKKβ,” Journal of Virology, vol. 84, no. 14, pp. 7267–7277, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  112. E. A. Slee, B. Benassi, R. Goldin et al., “Phosphorylation of Ser312 contributes to tumor suppression by p53 in vivo,” Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 45, pp. 19479–19484, 2010. View at Publisher · View at Google Scholar · View at PubMed
  113. A. Cheema, C. D. Knights, M. Rao et al., “Functional mimicry of the acetylated C-terminal tail of p53 by a SUMO-1 acetylated domain, SAD,” Journal of Cellular Physiology, vol. 225, no. 2, pp. 371–384, 2010. View at Publisher · View at Google Scholar · View at PubMed
  114. S. Tornaletti and G. P. Pfeifer, “Complete and tissue-independent methylation of CpG sites in the p53 gene: implications for mutations in human cancers,” Oncogene, vol. 10, no. 8, pp. 1493–1499, 1995.
  115. A. Deffie, H. Wu, V. Reinke, and G. Lozano, “The tumor suppressor p53 regulates its own transcription,” Molecular and Cellular Biology, vol. 13, no. 6, pp. 3415–3423, 1993.
  116. R. Wolkowicz and V. Rotter, “The DNA binding regulatory domain of p53: see the C,” Pathologie Biologie, vol. 45, no. 10, pp. 785–796, 1997.
  117. F. Fiordaliso, A. Leri, D. Cesselli et al., “Hyperglycemia activates p53 and p53-regulated genes leading to myocyte cell death,” Diabetes, vol. 50, no. 10, pp. 2363–2375, 2001.
  118. K. A. Field, D. Holowka, and B. Baird, “FcεRI-mediated recruitment of p53/56(lyn) to detergent-resistant membrane domains accompanies cellular signaling,” Proceedings of the National Academy of Sciences of the United States of America, vol. 92, no. 20, pp. 9201–9205, 1995. View at Publisher · View at Google Scholar
  119. W. Zhang, R. P. Trible, and L. E. Samelson, “LAT palmitoylation: its essential role in membrane microdomain targeting and tyrosine phosphorylation during T cell activation,” Immunity, vol. 9, no. 2, pp. 239–246, 1998.
  120. C.-H. Tang and E. A. Grimm, “Depletion of endogenous nitric oxide enhances cisplatin-induced apoptosis in a p53-dependent manner in melanoma cell lines,” Journal of Biological Chemistry, vol. 279, no. 1, pp. 288–298, 2004. View at Publisher · View at Google Scholar · View at PubMed
  121. C. S. Cobbs, T. R. Whisenhunt, D. R. Wesemann, L. E. Harkins, E. G. Van Meir, and M. Samanta, “Inactivation of wild-type p53 protein function by reactive oxygen and nitrogen species in malignant glioma cells,” Cancer Research, vol. 63, no. 24, pp. 8670–8673, 2003.
  122. D. W. Meek and W. Eckhart, “Phosphorylation of p53 in normal and simian virus 40-transformed NIH 3T3 cells,” Molecular and Cellular Biology, vol. 8, no. 1, pp. 461–465, 1988.
  123. D. W. Meek, S. Simon, U. Kikkawa, and W. Eckhart, “The p53 tumour suppressor protein is phosphorylated at serine 389 by casein kinase II,” EMBO Journal, vol. 9, no. 10, pp. 3253–3260, 1990.
  124. A. Sundqvist, G. Liu, A. Mirsaliotis, and D. P. Xirodimas, “Regulation of nucleolar signalling to p53 through NEDDylation of L11,” EMBO Reports, vol. 10, no. 10, pp. 1132–1139, 2009. View at Publisher · View at Google Scholar · View at PubMed
  125. M. Hollstein and P. Hainaut, “Massively regulated genes: the example of TP53,” Journal of Pathology, vol. 220, no. 2, pp. 164–173, 2010. View at Publisher · View at Google Scholar · View at PubMed
  126. S. Carter and K. H. Vousden, “p53-Ubl fusions as models of ubiquitination, sumoylation and neddylation of p53,” Cell Cycle, vol. 7, no. 16, pp. 2519–2528, 2008.
  127. U. P. Steinbrecher, M. Fisher, J. L. Witztum, and L. K. Curtiss, “Immunogenicity of homologous low density lipoprotein after methylation, ethylation, acetylation, or carbamylation: generation of antibodies specific for derivatized lysine,” Journal of Lipid Research, vol. 25, no. 10, pp. 1109–1116, 1984.
  128. K. L. Moore, “The biology and enzymology of protein tyrosine O-sulfation,” Journal of Biological Chemistry, vol. 278, no. 27, pp. 24243–24246, 2003. View at Publisher · View at Google Scholar · View at PubMed
  129. C. Seibert and T. P. Sakmar, “Toward a framework for sulfoproteomics: synthesis and characterization of sulfotyrosine-containing peptides,” Biopolymers, vol. 90, no. 3, pp. 459–477, 2008. View at Publisher · View at Google Scholar · View at PubMed
  130. M. J. Stone, S. Chuang, X. Hou, M. Shoham, and J. Z. Zhu, “Tyrosine sulfation: an increasingly recognised post-translational modification of secreted proteins,” New Biotechnology, vol. 25, no. 5, pp. 299–317, 2009. View at Publisher · View at Google Scholar
  131. J. W. Kehoe and C. R. Bertozzi, “Tyrosine sulfation: a modulator of extracellular protein-protein interactions,” Chemistry and Biology, vol. 7, no. 3, pp. R57–R61, 2000. View at Publisher · View at Google Scholar
  132. Y. B. Ouyang, W. S. Lane, and K. L. Moore, “Tyrosylprotein sulfotransferase: purification and molecular cloning of an enzyme that catalyzes tyrosine O-sulfation, a common posttranslational modification of eukaryotic proteins,” Proceedings of the National Academy of Sciences of the United States of America, vol. 95, no. 6, pp. 2896–2901, 1998. View at Publisher · View at Google Scholar
  133. J. M. Gao, R. L. Xiang, L. Jiang et al., “Sulfated tyrosines 27 and 29 in the N-terminus of human CXCR3 participate in binding native IP-10,” Acta Pharmacologica Sinica, vol. 30, no. 2, pp. 193–201, 2009. View at Publisher · View at Google Scholar · View at PubMed
  134. C. C. Huang, M. Venturi, S. Majeed et al., “Structural basis of tyrosine sulfation and V-gene usage in antibodies that recognize the HIV type 1 coreceptor-binding site on gp120,” Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 9, pp. 2706–2711, 2004. View at Publisher · View at Google Scholar · View at PubMed
  135. J. Liu, S. Louie, W. Hsu, K. M. Yu, H. B. Nicholas, and G. L. Rosenquist, “Tyrosine sulfation is prevalent in human chemokine receptors important in lung disease,” American Journal of Respiratory Cell and Molecular Biology, vol. 38, no. 6, pp. 738–743, 2008. View at Publisher · View at Google Scholar · View at PubMed
  136. P. W. Cheng, T. F. Boat, K. Cranfill, J. R. Yankaskas, and R. C. Boucher, “Increased sulfation of glycoconjugates by cultured nasal epithelial cells from patients with cystic fibrosis,” Journal of Clinical Investigation, vol. 84, no. 1, pp. 68–72, 1989.
  137. W. Hsu, G. L. Rosenquist, A. A. Ansari, and M. E. Gershwin, “Autoimmunity and tyrosine sulfation,” Autoimmunity Reviews, vol. 4, no. 7, pp. 429–435, 2005. View at Publisher · View at Google Scholar · View at PubMed
  138. A. Rossi, J. Bonaventure, A. L. Delezoide, A. Superti-Furga, and G. Cetta, “Undersulfation of cartilage proteoglycans ex vivo and increased contribution of amino acid sulfur to sulfation in vitro in McAlister dysplasia/atelosteogenesis type 2,” European Journal of Biochemistry, vol. 248, no. 3, pp. 741–747, 1997.
  139. Z. R. Yang, “Predicting sulfotyrosine sites using the random forest algorithm with significantly improved prediction accuracy,” BMC Bioinformatics, vol. 10, Article ID 1471, p. 361, 2009. View at Publisher · View at Google Scholar · View at PubMed
  140. C. H. Jen and J. A. Leary, “A competitive binding study of chemokine, sulfated receptor, and glycosaminoglycan interactions by nano-electrospray ionization mass spectrometry,” Analytical Biochemistry, vol. 407, no. 1, pp. 134–140, 2010. View at Publisher · View at Google Scholar · View at PubMed
  141. K. D. Wilkinson, “Protein ubiquitination: a regulatory post-translational modification,” Anti-Cancer Drug Design, vol. 2, no. 2, pp. 211–229, 1987.
  142. M. Rechsteiner, “Ubiquitin-mediated pathways for intracellular proteolysis,” Annual Review of Cell Biology, vol. 3, pp. 1–30, 1987.
  143. C. M. Pickart, “Targeting of substrates to the 26S proteasome,” FASEB Journal, vol. 11, no. 13, pp. 1055–1066, 1997.
  144. E. T. H. Yeh, L. Gong, and T. Kamitani, “Ubiquitin-like proteins: new wines in new bottles,” Gene, vol. 248, no. 1-2, pp. 1–14, 2000. View at Publisher · View at Google Scholar
  145. C. S. Shi and J. H. Kehrl, “TRAF6 and A20 regulate lysine 63-linked ubiquitination of Beclin-1 to control TLR4-induced Autophagy,” Science Signaling, vol. 3, no. 123, p. ra42, 2010. View at Publisher · View at Google Scholar · View at PubMed
  146. X. Jin, H. Cheng, J. Chen, and D. Zhu, “RNF13: an emerging RING finger ubiquitin ligase important in cell proliferation,” FEBS Journal, vol. 278, no. 1, pp. 78–84, 2011. View at Publisher · View at Google Scholar · View at PubMed
  147. I. Bosanac, I. E. Wertz, B. Pan et al., “Ubiquitin binding to A20 ZnF4 is required for modulation of NF-kappaB signaling,” Molecular Cell, vol. 40, no. 4, pp. 548–557, 2010. View at Publisher · View at Google Scholar · View at PubMed
  148. A. Keutgens, X. Zhang, K. Shostak et al., “BCL-3 degradation involves its polyubiquitination through a FBW7-independent pathway and its binding to the proteasome subunit PSMB1,” Journal of Biological Chemistry, vol. 285, no. 33, pp. 25831–25840, 2010. View at Publisher · View at Google Scholar · View at PubMed
  149. P. C. Weber, S. J. Spatz, and E. C. Nordby, “Stable ubiquitination of the ICP0R protein of herpes simplex virus type 1 during productive infection,” Virology, vol. 253, no. 2, pp. 288–298, 1999. View at Publisher · View at Google Scholar · View at PubMed
  150. J. R. C. Bergeron, H. Huthoff, D. A. Veselkov et al., “The SOCS-box of HIV-1 vif interacts with elonginBC by induced-folding to recruit its Cul5-containing ubiquitin ligase complex,” PLoS Pathogens, vol. 6, no. 6, p. e1000925, 2010. View at Publisher · View at Google Scholar · View at PubMed
  151. C. A. Gutekunst, S. H. Li, H. Yi et al., “Nuclear and neuropil aggregates in Huntington's disease: relationship to neuropathology,” Journal of Neuroscience, vol. 19, no. 7, pp. 2522–2534, 1999.
  152. X. He and Q. Ma, “NRF2 cysteine residues are critical for oxidant/electrophile-sensing, Kelch-like ECH-associated protein-1-dependent ubiquitination-proteasomal degradation, and transcription activation,” Molecular Pharmacology, vol. 76, no. 6, pp. 1265–1278, 2009. View at Publisher · View at Google Scholar · View at PubMed
  153. J. M. Lee and J. A. Johnson, “An important role of Nrf2-ARE pathway in the cellular defense mechanism,” Journal of Biochemistry and Molecular Biology, vol. 37, no. 2, pp. 139–143, 2004.
  154. F. Colland, “The therapeutic potential of deubiquitinating enzyme inhibitors,” Biochemical Society Transactions, vol. 38, no. 1, pp. 137–143, 2010. View at Publisher · View at Google Scholar · View at PubMed
  155. L. Bedford, et al., “Ubiquitin-like protein conjugation and the ubiquitin-proteasome system as drug targets,” Nature Reviews Drug Discovery, vol. 10, no. 1, pp. 29–46, 2011.